Welch Group LLC Raises Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Welch Group LLC raised its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,550 shares of the medical equipment provider’s stock after acquiring an additional 342 shares during the quarter. Welch Group LLC’s holdings in Zimmer Biomet were worth $506,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Garde Capital Inc. bought a new stake in Zimmer Biomet during the 1st quarter valued at $29,000. Washington Trust Advisors Inc. bought a new stake in Zimmer Biomet during the first quarter valued at about $30,000. Columbia River Financial Group LLC bought a new stake in Zimmer Biomet during the first quarter valued at about $30,000. Accent Capital Management LLC bought a new stake in Zimmer Biomet during the first quarter valued at about $35,000. Finally, Cullen Frost Bankers Inc. boosted its holdings in shares of Zimmer Biomet by 1,452.4% in the 1st quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock valued at $37,000 after buying an additional 305 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $94.79 on Monday. Zimmer Biomet Holdings, Inc. has a 12-month low of $89.22 and a 12-month high of $114.72. The stock has a market cap of $18.78 billion, a P/E ratio of 23.06, a PEG ratio of 2.18 and a beta of 0.67. The company has a 50-day moving average price of $101.31 and a 200 day moving average price of $98.15. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.09. The firm had revenue of $2.08 billion during the quarter, compared to analysts’ expectations of $2.06 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. Zimmer Biomet’s revenue was up 7.0% compared to the same quarter last year. During the same period last year, the business earned $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is 23.36%.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on ZBH shares. Stifel Nicolaus raised their target price on shares of Zimmer Biomet from $115.00 to $118.00 and gave the company a “buy” rating in a research note on Friday, September 19th. Rothschild Redb upgraded shares of Zimmer Biomet to a “strong-buy” rating in a research note on Thursday, September 18th. Evercore ISI decreased their target price on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating for the company in a report on Tuesday, October 7th. Rothschild & Co Redburn assumed coverage on shares of Zimmer Biomet in a research note on Thursday, September 18th. They set a “buy” rating and a $130.00 price objective for the company. Finally, Royal Bank Of Canada set a $111.00 price objective on Zimmer Biomet in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $112.67.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the firm’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the sale, the senior vice president owned 6,833 shares of the company’s stock, valued at $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.39% of the stock is currently owned by company insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.